Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10166032 | 0.92 | PIK3CA (0.39) | IKBKBMALT1 | |
| SCHEMBL1685179 | 0.86 | MAPKAPK5 (0.44) | IKBKBMCHR1MCHR2HSD17B10MALT1 | |
| SCHEMBL1685180 | 0.86 | MAPKAPK5 (0.44) | IKBKBMCHR1MCHR2HSD17B10MALT1 | |
| SCHEMBL10166155 | 0.83 | TTK (0.35) | IKBKB | |
| SCHEMBL12618755 | 0.83 | HSD17B10 (0.44) | IKBKBMCHR1MCHR2HSD17B10MALT1 | |
| SCHEMBL10166349 | 0.83 | BRAF (0.42) | IKBKB | |
| SCHEMBL10166358 | 0.83 | BRAF (0.38) | — | |
| SCHEMBL10166145 | 0.82 | BRAF (0.42) | IKBKB | |
| SCHEMBL10166148 | 0.82 | POLB (0.40) | IKBKBCAMK2DALDH1A1GAA | |
| SCHEMBL10166838 | 0.82 | FYN (0.45) | IKBKBROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | IKBKB 135/4885MCHR1 4798/4885MCHR2 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.